Long-term follow-up of a RCT: Nivolumab plus cabozantinib vs. sunitinib in first-line treatment for advanced renal cell carcinoma.

Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)

Commentary: CheckMate 9ER update confirms first-line nivolumab plus cabozantinib benefits for advanced RCC – medwire News

Original Study: Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma – New England Journal of Medicine

Commentary from the author on Twitter (thread – click for more)

1/ CheckMate-9ER extended f/u (media f/u=32.9mo) results out in @TheLancetOncol: preplanned final OS analysis, updated PFS, OR & safety of Cabo/Nivo vs. Sun in 1L RCC. Also includes prespecified & post-hoc subgroup analyses. https://t.co/OJduO7Q2ar@OncoAlert @DanaFarber_GU pic.twitter.com/0EQN5gWu5I

— Toni Choueiri, MD (@DrChoueiri) June 8, 2022